Mondobiotech

Navigenics’ lower-priced program to incorporate genetic risk data in patients’ annual medical checkup raises questions as to whether personal genomics firms should be broadly marketing their services to physicians.

Details of the deal are sparse, but the partners said they hope their research will lead to the development of genetic tests that can gauge patients’ predisposition to rare diseases and help target individuals most likely to respond to drugs made by MondoBiotech.

Short Reads

Premium

Broad Institute, Expression Analysis, Helicos BioSciences, University of Texas at Austin, Applied Biosystems, University of Georgia, ABRF, Genomatix, Illumina, Mondobiotech, 23andMe, Kapa Biosystems

BioArray Briefs

Premium

Cancer Research UK, Fluidigm, Fox Chase Cancer Center, BioDiscovery, Mondobiotech, 23andMe

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.